ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties

Chinese Journal of Cancer

Volumn 31, Issue 3, 2012, Pages 150-158

  Wang, Fang ^a   Liang, Yong Ju ^a   Wu, Xing Ping ^a   Su, Xiao Dong ^a   Fu, Li Wu ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ABCG2; Multidrug resistance; Nude mice; S1 M1 80; Xenograft

Indexed keywords

1,2,3,4,6,7,12,12A OCTAHYDRO 6 ISOBUTYL 9 METHOXY 1,4 DIOXOPYRAZINO[1',2':1,6]PYRIDO[3,4 B]INDOLE 3 PROPANOIC ACID TERT BUTYL ESTER; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DOXORUBICIN; MITOXANTRONE; TOPOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ADENOSINE; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; KB CELLS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOXANTRONE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; RHODAMINE 123; TOPOTECAN;

EID: 84863243959     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10310     Document Type: Article

References (28)

1. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr, 2001,33:453-458.
2. Sarkadi B, Homolya L, Szakacs G, et al. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev, 2006,86:1179-1236.
3. Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 2006,5:219-234.
4. Allen JD, Schinkel AH. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther, 2002,1: 427-434.
5. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res, 2001,61:3458-3464.
6. Shimano K, Satake M, Okaya A, et al. Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1. Am J Pathol, 2003,163:3-9.
7. Krishnamurthy P, Ross DD, Nakanishi T, et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem, 2004,279:24218-24225.
8. Maliepaard M, van Gastelen MA, de Jong LA, et al. Over expression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res, 1999,59:4559-4563.
9. Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-ex pressing cells. Cancer Res, 1999,59:5938-5946.
10. Kawabata S, Oka M, Shiozawa K, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Biophys Res Commun, 2001,280:1216-1223.
11. Tsunoda S, Okumura T, Ito T, et al. ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology, 2006,71:251-258.
12. Svirnovski AI, Shman TV, Serhiyenka TF, et al. ABCB1 and ABCG2 proteins, their functional activity and gene expression in concert with drug sensitivity of leukemia cells. Hematology, 2009,14:204-212.
13. Damiani D, Tiribelli M, Michelutti A, et al. Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. Leuk Res, 2010,34:942-945.
14. Nakanishi T, Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer, 2012,31:73-99.
15. Kim YH, Ishii G, Goto K, et al. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer, 2009,65: 105-111.
16. Jonker JW, Buitelaar M, Wagenaar E, et al. The breast cancer resistance protein protects against a major chlorophyll-de rived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A, 2002,99:15649-15654.
17. Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-over expressing cells. Cancer Res, 2001,61:6635-6639.
18. Dai CL, Xiong HY, Tang LF, et al. Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemother Pharmacol, 2007,60:741-750.
19. Sumizawa T, Chuman Y, Sakamoto H, et al. Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein. Somat Cell Mol Genet, 1994,20:423-435.
20. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with over expression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci, 2000,113:2011-2021.
21. Dai CL, Tiwari AK, Wu CP, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res, 2008,68:7905-7914.
22. Shi Z, Liang YJ, Chen ZS, et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther, 2006,5: 39-47.
23. Cai MJ, Xie RF, Han L, et al. Effect of RNAi-mediated LRIG3 gene silencing on proliferation of glioma GL15 cells and expression of PCNA and Ki-67. Ai Zheng, 2009,28:1-4.
24. Zhang JY, Wu HY, Xia XK, et al. Anthracenedione derivative 1403P-3 induces apoptosis in KB and KBv200 cells via reactive oxygen species-in dependent mitochondrial pathway and death receptor pathway. Cancer Biol Ther, 2007,6:1413-1421.
25. Fu L, Liang Y, Deng L, et al. Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother Pharmacol, 2004,53:349-356.
26. Schecter RL, Woo A, Duong M, et al. In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model. Cancer Res, 1991,51:1434-1442.
27. Mi YJ, Liang YJ, Huang HB, et al. Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res, 2010,70:7981-7991.
28. Allen JD, Jackson SC, Schinkel AH. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance. Cancer Res, 2002,62: 2294-2299.